A novel vaccine for acute myeloid leukemia (AML) demonstrated encouraging results in a Phase 3 clinical trial, according to announcements from drug developer Sellas Life Sciences and Memorial Sloan Kettering Cancer Center on Tuesday. The vaccine, galinpepimut-S (GPS), showed a 41 percent reduction in the risk of death compared to alternative treatments in a study involving 126 patients.
The trial focused on AML patients who had achieved at least a second complete remission or complete remission with incomplete recovery, meaning the cancer had been successfully controlled multiple times but residual disease remained. These patients were also ineligible for bone marrow transplantation, a common but not universally applicable treatment for AML. Acute myeloid leukemia, which affects approximately 20,000 people annually in the United States, is typically treated with chemotherapy; however, high rates of relapse remain a significant challenge.
GPS differs from other recent cancer vaccines, such as intismeran, which earned attention earlier this year for its success in a Phase 3 melanoma trial. While intismeran is a personalized mRNA vaccine produced from individual tumor samples, GPS is designed as a standardized, off-the-shelf peptide vaccine that can be administered broadly to AML patients without customization. David Scheinberg, chairman of the Experimental Therapeutics Center at Memorial Sloan Kettering and the vaccine’s developer, highlighted this distinction, noting that GPS eliminates the need for patient-specific manufacturing.
According to Sellas, patients treated with the vaccine had a median overall survival of 24 months, compared to 14.7 months for those receiving other treatments. The vaccine was generally well tolerated, with the most frequent side effects limited to localized injection site reactions. Full trial data, including secondary endpoints such as leukemia-free and relapse-free survival, are expected to be released at a forthcoming medical conference.
Experts unaffiliated with the study emphasized the significance of these findings for a patient population with limited treatment options. Ravi Majeti, professor of medicine at Stanford University School of Medicine, described the trial cohort as a small subgroup of AML patients “who don’t have any good therapy options,” but also advised caution until full data become available.
Both GPS and intismeran work by activating the immune system to recognize and destroy cancer cells that often evade traditional therapies. Peptide vaccines like GPS deliver specific proteins to elicit this immune response, while mRNA vaccines encourage cells to produce their own tumor-specific proteins. Scheinberg expressed optimism that the success of these differing approaches could signal the start of a new era in cancer vaccine development, with ongoing plans to evaluate GPS in other leukemias and cancers.
Sellas intends to submit data for regulatory approval from the U.S. Food and Drug Administration in the first half of 2027.
